HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Radioresistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism.

Abstract
Highly glycolytic cervical cancers largely resist treatment by cisplatin and coadministered pelvic irradiation as the present standard of care. In this study, we investigated the effects of inhibiting glycolysis and thiol redox metabolism to evaluate them as alternate treatment strategies in these cancers. In a panel of multiple cervical cancer cell lines, we evaluated sensitivity to inhibition of glycolysis (2-deoxyglucose, 2-DG) with or without simultaneous inhibition of glutathione and thioredoxin metabolism (BSO/AUR). Intracellular levels of total and oxidized glutathione, thioredoxin reductase activity, and indirect measures of intracellular reactive oxygen species were compared before and after treatment. Highly radioresistant cells were the most sensitive to 2-DG, whereas intermediate radioresistant cells were sensitive to 2-DG plus BSO/AUR. In response to 2-DG/BSO/AUR treatment, we observed increased levels of intracellular oxidized glutathione, redox-sensitive dye oxidation, and decreased glucose utilization via multiple metabolic pathways including the tricarboxylic acid cycle. 2-DG/BSO/AUR treatment delayed the growth of tumors composed of intermediate radioresistant cells and effectively radiosensitized these tumors at clinically relevant radiation doses both in vitro and in vivo Overall, our results support inhibition of glycolysis and intracellular redox metabolism as an effective alternative drug strategy for the treatment of highly glycolytic and radioresistant cervical cancers.Significance: This study suggests a simple metabolic approach to strike at an apparent Achilles' heel in highly glycolytic, radioresistant forms of cervical cancers, possibly with broader applications in cancer therapy. Cancer Res; 78(6); 1392-403. ©2018 AACR.
AuthorsRamachandran Rashmi, Xiaojing Huang, John M Floberg, Adnan E Elhammali, Michael L McCormick, Gary J Patti, Douglas R Spitz, Julie K Schwarz
JournalCancer research (Cancer Res) Vol. 78 Issue 6 Pg. 1392-1403 (03 15 2018) ISSN: 1538-7445 [Electronic] United States
PMID29339540 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright©2018 American Association for Cancer Research.
Chemical References
  • Reactive Oxygen Species
  • Lactic Acid
  • Auranofin
  • Buthionine Sulfoximine
  • Thioredoxins
  • Deoxyglucose
  • Glutathione
Topics
  • Animals
  • Auranofin (pharmacology)
  • Buthionine Sulfoximine (pharmacology)
  • Cell Death (drug effects)
  • Cell Line, Tumor
  • Citric Acid Cycle (drug effects)
  • Deoxyglucose (pharmacology)
  • Female
  • Glutathione (metabolism)
  • Glycolysis (drug effects)
  • Humans
  • Lactic Acid (metabolism)
  • Mice, Nude
  • Oxidation-Reduction
  • Radiation Tolerance (drug effects)
  • Reactive Oxygen Species (metabolism)
  • Thioredoxins (metabolism)
  • Uterine Cervical Neoplasms (drug therapy, metabolism, pathology, radiotherapy)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: